UNMC commences clinical trial of remdesivir for treating COVID-19
Category: #health  By Pankaj Singh  Date: 2020-02-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

UNMC commences clinical trial of remdesivir for treating COVID-19

A controlled, randomized clinical trial to evaluate the efficacy and safety of the investigational antiviral, remdesivir, in COVID-19 patients has reportedly commenced at the University of Nebraska Medical Center (UNMC) in Omaha.

According to sources, this clinical trial is being sponsored by NIAID (National Institute of Allergy and Infectious Diseases), a division of the National Institutes of Health (NIH).

It is the first clinical study in the U.S. to determine an experimental therapy for COVID-19. The first participant to register in the clinical trial is an American who was brought to the UNMC campus after being quarantined on the Diamond Princess cruise ship that berthed in Yokohama, Japan. The person agreed to participate in the clinical study.

Presently, there are no particular treatments approved by the U.S. FDA to treat people with COVID-19. On Feb. 24, the WHO ( World Health Organization ) had recorded 77,262 confirmed COVID-19 cases and 2,595 deaths in China and 2,069 confirmed cases and 23 deaths in 29 other nations.

As per CDC (Centers for Disease Control and Prevention), there have been fourteen confirmed cases recorded in the U.S. and further 39 cases among persons deported to the U.S.

Clinical studies of remdesivir are also progressing in China. NIAID developed the present study taking those designs into account and in line with consultations convened by the WHO on the advancement of clinical trials for COVID-19 patients.

Anthony S. Fauci, M.D., the United States Coronavirus Task Force member and Director of NIAID, said that there is an urgent need for an effective and safe treatment for COVID-19. Fauci added that though remdesivir has been administered to a few COVID-19 patients, they do not possess the data indicating it could enhance clinical results.

A placebo-controlled, randomized clinical trial is the gold standard for defining experimental treatment benefit in coronavirus patients.

Source Link - https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

TikTok to donate 4 Lakh safety suits to Indian healthcare workers
TikTok to donate 4 Lakh safety suits to Indian healthcare workers
By Pankaj Singh

Amidst lowering availability of medical equipment and safety gear in India during the current COVID-19 crisis, Chinese video-sharing company, TikTok has made a generous gesture by announcing that it will donate ab...

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...